Search Results

You are looking at 1 - 10 of 56 items for :

  • "kidney disease" x
  • Refine by Access: All x
Clear All
Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, David Josephson, Timothy M. Kuzel, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Philippe E. Spiess, Jue Wang, and Richard B. Wilder

nephrectomy has well-established oncologic outcomes data comparable to radical nephrectomy, 14 , 17 – 19 which can lead to an increased risk of chronic kidney disease 20 , 21 that is associated with increased risks of cardiovascular morbidity and mortality

Full access

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Graeme B. Bolger, Barry Boston, Michael A. Carducci, Toni K. Choueiri, Robert A. Figlin, Mayer Fishman, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Anne Kessinger, Timothy M. Kuzel, Paul H. Lange, Ellis G. Levine, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Bruce G. Redman, Cary N. Robertson, Lawrence H. Schwartz, Joel Sheinfeld, and Jue Wang

Full access

Chunkit Fung, Paul C. Dinh Jr, Sophie D. Fossa, and Lois B. Travis

,214 participants in the Platinum Study. CBM score accounts for the number and severity of the following adverse health outcomes: peripheral sensory neuropathy, autonomic neuropathy, hearing loss/damage, tinnitus, Raynaud phenomenon, pain, kidney disease

Full access

Martin J. Edelman, Daniel P. Raymond, Dwight H. Owen, Michelle B. Leavy, Kari Chansky, Sriram Yennu, Felix G. Fernandez, Carolyn J. Presley, Tithi Biswas, Gwendolyn P. Quinn, Matthew B. Schabath, Seth Sheffler-Collins, Laura Chu, and Richard E. Gliklich

of the participant, disease, and provider (left column) and treatments of interest (center column) that should be captured to support risk adjustment. Abbreviations: CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic

Full access

Sarju Ganatra, Sourbha S. Dani, Robert Redd, Kimberly Rieger-Christ, Rushin Patel, Rohan Parikh, Aarti Asnani, Vigyan Bang, Katherine Shreyder, Simarjeet S. Brar, Amitoj Singh, Dhruv S. Kazi, Avirup Guha, Salim S. Hayek, Ana Barac, Krishna S. Gunturu, Corrine Zarwan, Anne C. Mosenthal, Shakeeb A. Yunus, Amudha Kumar, Jaymin M. Patel, Richard D. Patten, David M. Venesy, Sachin P. Shah, Frederic S. Resnic, Anju Nohria, and Suzanne J. Baron

, cardiomyopathy, congestive heart failure, moderate to severe valvular heart disease, or ischemic stroke. Data Acquisition Patient demographics, comorbidities (including history of cancer, cardiovascular risk factors, preexisting CVD, chronic kidney disease [CKD

Full access

Siyang Leng, Yizhen Chen, Wei-Yann Tsai, Divaya Bhutani, Grace C. Hillyer, Emerson Lim, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Suzanne Lentzsch, and Alfred I. Neugut

, including acute kidney injury, chronic kidney disease, use of hemodialysis, osteoporosis, osteopenia, and hypercalcemia. Comorbidity score was assessed using the Klabunde adaptation of the Charlson comorbidity index. 21 The initial antineoplastic regimen

Full access

Priya Wanchoo, Chris Larrison, Carol Rosenberg, Naomi Ko, Cynthia Cantril, Naomi Moeller, Ruchit Parikh, and Ana-Marija Djordjevic

therapy, 16% would continue anastrozole and 7% would administer either single-agent or combination chemotherapy. Thus, 1 in 4 individuals would not make the optimal choice. Abbreviations: CAD, coronary artery disease; CKD, chronic kidney disease; COPD

Full access

Michael Xiang and Elizabeth A. Kidd

; SCC, squamous cell carcinoma. Determination of Study Variables and Outcomes Comorbidity was calculated using the Charlson comorbidity index as previously described. 17 Presence of chronic kidney disease was determined from claims before diagnosis, and

Full access

Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo

and health services using claims from 1 year preceding the DLBCL diagnosis. In particular, chronic kidney disease was defined as occurrence of any of the following codes from the ICD-9: 582.*, 583.*, 585.*, 586, or 588.*. Health services were

Full access

Martha Isabel Junio Parroco and Genalin Fabul Amparo

such as age and body mass index are not significant as well as comorbidities which includes deep vein thrombosis and chronic kidney disease, stage, and number of sexual partners were not significant with p-values above 0.05. For histopathology, only